Search the Newsreel

Honasa Consumer gain over 3% after solid Q1 performance — Analysts mixed, two raise price targets

Stocks to Watch Today, August 14, 2026: HONASA CONSUMER, DCW, Avanti Feeds, Tata Motors Passenger Vehicles and Technocraft Industries

Stocks to Watch Today: Piramal Pharma, Tata Motors PV, LG Electronics, Honasa Consumer, Welspun Living,...

Genasys (NASDAQ:GNSS) Posts Earnings Results, Misses Estimates By $0.08 EPS

Genasys (NASDAQ:GNSS) reported its earnings, missing consensus estimates with an EPS of ($0.10) against an expected ($0.02), and revenue of $7.29 million against $15.47 million. Despite the miss, management reaffirmed its fiscal 2026 outlook for record revenue and profitability, citing a $69 million backlog, …

Stocks in news: Indigo Paints, LG Electronics India, Tata Motors PV, Honasa Consumer, Ashok Leyland, Physi

Genasys signals fiscal 2026 record year outlook as it expects to complete initial $9M CROWS delivery within the year

Earnings Call Insights: Genasys Inc. (GNSS) Q3 2026 MANAGEMENT VIEW * “Revenue for the fiscal third quarter was $7.3 million compared to $9.9 million in the prior year period,” and CEO Richard Danforth said the decline was driven by “2 timing-related factors,” including “the …

Renasant Corporation declares $0.24 quarterly dividend By Investing.com

Renasant Corporation announced a quarterly cash dividend of $0.24 per share, payable on September 30, 2026, to shareholders of record as of September 16, 2026. The company, which is the parent of Renasant Bank, manages approximately $27.0 billion in assets and operates 279 offices …

Renasant Corp. (RNST) Q2 2026 Earnings Report - Results, Call & Slides

Genasys Inc earnings missed by $0.12, revenue fell short of estimates

Genasys Inc (NASDAQ: GNSS) reported third-quarter earnings per share (EPS) of $-0.100, missing analyst estimates by $0.12, and revenue of $7.3M, significantly below the consensus of $19.2M. The company's stock has seen a -4.470% decline in the last three months but is up 4.270% …

Nasdaq Firm Makes Historic Shift to Ethereum-Based Treasury

BioNexus Gene Lab Corp., a Nasdaq-listed biotech firm, has announced its adoption of an Ethereum-focused treasury strategy, becoming the first public company to do so. This decision was influenced by Ethereum's growing institutional credibility, its Proof-of-Stake yield capabilities, and Wyoming's blockchain-friendly regulations. The company …

Earnings call transcript: Genasys misses Q3 2026 estimates as stock slips after hours

Genasys: Fiscal Q3 Earnings Snapshot

This article provides a brief earnings snapshot for Genasys' fiscal Q3. Without further details, it indicates a focus on financial reporting for the quarter.

Genasys Inc. (NASDAQ: GNSS) boosts margins as Q3 revenue slips to $7.3M

Genasys Inc. reported a Q3 2026 revenue of $7.3 million, a decrease from the previous year, but saw significant improvements in profitability with gross margin rising to 57.1%. The company narrowed its GAAP net loss and improved adjusted EBITDA, attributing these gains to a …

Genasys Inc. (GNSS) boosts revenue yet turns to stockholders’ deficit and adds high-cost debt

Genasys enters fiscal Q4 with backlog above $69M, expects record year

Genasys Inc. reported its fiscal Q3 2026 financial results, with revenue of $7.3 million and a GAAP net loss of $4.7 million. Despite supply chain issues and payment delays affecting the quarter, the company secured significant new orders and extended its term loan maturity. …

Zenas BioPharma (NASDAQ:ZBIO) Issues Earnings Results

Zenas BioPharma (NASDAQ:ZBIO) Stock Price Down 6.6% on Disappointing Earnings

Zenas BioPharma (NASDAQ:ZBIO) experienced a 6.6% stock price drop after reporting disappointing quarterly earnings, with an EPS of $(1.77) against an estimated $(1.12) and revenue of $1 million against a $15 million forecast. Despite the earnings miss, analysts generally maintain a "Moderate Buy" rating …

Stocks to Watch for August 14: Tata Motors PV, LG Electronics, Honasa Consumer, Max Fin Services and more

Can Cognyte Software (NASDAQ:CGNT) Keep Its Momentum?

Cognyte Software (NASDAQ:CGNT) has gained attention as its shares crossed above a long-term trading trend, indicating strengthening momentum. The company, a security analytics provider for government and critical infrastructure, showed resilient revenue in its latest quarterly update, although profitability remains a key challenge. Demand …

Earnings call transcript: Honasa Consumer Q1 2026 growth and margins lift shares

Renasant Corporation Declares Quarterly Dividend

Renasant Corporation TUPELO, Miss., Aug. 13, 2026 (GLOBE NEWSWIRE) -- The board of directors of Renasant Corporation (NYSE: RNST) approved the payment of a quarterly cash dividend of twenty-four cents ($0.24) per share to be paid September 30, 2026, to shareholders of record as …

Honasa Consumer consolidated net profit rises 118.36% in the June 2026 quarter

Dynasty Fine Wines Sets Board Meeting to Approve 2026 Interim Results

Honasa Consumer Q1 Results: Mamaearth parent posts record profit of Rs 90 crore; revenue up 27% YoY

Zenas BioPharma, Inc. 2026: Revenue $1M, Net income ($111.46M), EPS ($1.77) — 10-Q Summary

Zenas BioPharma, Inc. (ZBIO) reported its financial results for the quarter ended 2026, showing revenue of $1M and a net loss of ($111.46M), with a diluted loss per share of ($1.77). These figures represent a significant decrease in revenue and an increase in net …

Form 8K Zenas Biopharma Inc For: 13 August By Investing.com

This article is a brief financial announcement from Investing.com, stating that Zenas Biopharma Inc. filed a Form 8K on August 13th. The filing is related to the company's financial activities and includes the stock symbol ZBIO, which showed a -6.68% change. The content primarily …

Earnings Flash (ZBIO) Zenas BioPharma Posts Q2 Loss $1.77 a Share, vs. FactSet Est of $1.12 Loss

Zenas BioPharma (ZBIO) announced a Q2 loss of $1.77 per share, which is significantly wider than FactSet's estimated loss of $1.12 per share. The company reported Q2 revenue of $1.0 million. Zenas BioPharma is a clinical-stage biopharmaceutical company focused on autoimmune diseases with lead …

Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Zenas BioPharma announced its second quarter 2026 financial results and provided a corporate update, highlighting the FDA's acceptance of the obexelimab BLA for IgG4-RD with a PDUFA date of May 27, 2027. The company also reported positive Phase 3 INDIGO trial results for obexelimab, …

Earnings Flash (ZBIO) Zenas BioPharma, Inc. Reports Q2 Revenue $1.0M

Zenas BioPharma Reports $111.5 Million Second-Quarter Net Loss

Zenas BioPharma (ZBIO) reported a second-quarter 2026 net loss of $111.5 million on $1.0 million in revenue, an increase from a $52.2 million net loss in the prior-year quarter. The company ended the quarter with $673.9 million in cash and investments, and its biologics …

Honasa Consumer Q1 results: Mamaearth-parent posts 118% YoY jump in profits; revenue climbs 27%; check numbers

Honasa Consumer Q1 results: Mamaearth-parent’s net profit surges 119% to Rs 90.4 crore, revenue up 27%

Honasa Consumer Q1 net profit more than doubles as general, modern trade grow over 40%

Honasa Consumer Q1 Results: Mamaearth Parent Posts Over 2x Jump In Profit; Margin Expands Sharply

Lynas Rare Earths (ASX:LYC) Shares May Be 24% Undervalued On Cash Flow

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Lynas Rare Earths has delivered a 146.7% return over the past three years, yet investors now face mixed valuation signals as the Discounted Cash Flow …

SINTX Technologies Regains Compliance with Nasdaq Stockholders’ Equity Requirement

SINTX Technologies announced it has regained compliance with Nasdaq's minimum stockholders' equity requirement of $2.5 million, as confirmed by the Nasdaq Listing Qualifications Staff. The company reported stockholders' equity of approximately $4.83 million in its recent Form 10-Q. This allows SINTX to focus on …